Thus, DEL-1 can resolve IL-17–mediated pathologies, such as inflammatory bone loss and multiple sclerosis, by suppressing inflammation with various antiinflammatory actions that depend on interaction of DEL-1 with integrins. Here, EDIL3 is linked to multiple sclerosis.